目的:比较苏为坦和贝他根在治疗原发性开角型青光眼的疗效,以更好地指导临床应用。方法:本院2008-12/2010-12共46例46眼原发性开角型青光眼患者入选本研究,其中苏为坦组23例,贝他根组23例,两组分别使用苏为坦和贝他根滴眼液,每晚点药1次(1滴/次),治疗周期为12wk,每月随访1次。每日取5个时间节点,比较两组在治疗前后的眼压变化,观察不良反应,应用SPSS16.0软件进行统计学分析。结果:两组患者用药12wk后眼压均明显下降,苏为坦组眼压从24.3±2.02mmHg降至16.1±1.34mmHg,贝他根组眼压从24.99±1.38mmHg降至15.56±0.68mmHg,波幅下降幅度(用药前后波幅差值/用药前波幅值),苏为坦组为36.7%,贝他根组为35.8%,用药前后各时间节点中,两组间的眼压值变化,在夜间12:00苏为坦组眼压下降优于贝他根组(F=4.25,P=0.045),而其他时间节点两组变化差异无统计学意义。结论:苏为坦和贝他根治疗原发性青光眼降眼压疗效明显平稳,无明显毒副作用,苏为坦在降低夜间眼压方面优于贝他根。

AIM:To evaluate and compare the effects of Travatan and Betagan in the treatment of primary open angle glaucoma.METHODS:Forty-six patients with primary open angle glaucoma were enrolled in this study from December 2008 to December 2010.The patients were divided into two groups.Patients in proup A were prescribed with Travatan one drop every night and group B with Betagan one drop everynight.All the patients were treated for 12 weeks and were followed up every month.Intraocular pressure was measured at five time points before and every follow up day after treatment,and side effects of the two drugs,if any,were recorded.Data were analyzed by using the SPSS 16.0 software.RESULTS:The average intraocular pressure was significantly reduced 12 weeks after treatment in both groups.The average intraocular pressure in group A decreased from 24.3±2.02mmHg to 16.1±1.34mmHg,while that in group B decreased from 24.99±1.38mmHg to 15.56±0.68mmHg.The decreasing rate of two groups was 36.7% and 35.8%,respectively.The intraocular pressure changes at mid-night(12:00pm) were bigger in group A than in group B(F=4.25,P=0.045),but there was no significant difference in other time points between the two groups.No obvious side effect was observed.CONCLUSION:Both Travatan and Betagan could lower the IOP effectively and stably in the treatment of primary open-angle glaucoma,and could be tolerated well without obvious side effects.Travatan could reduce intraocular pressure more than Betagan at mid-night.

R775